Filing summary: quarter ended March 31, 2013
Entity note: Although the request identifies SELLAS Life Sciences Group, Inc., the supplied 10-Q is for Galena Biopharma, Inc. Investors should verify the issuer and filing before relying on this summary.
Business context and reporting period
Galena described itself as a development-stage biopharmaceutical company focused on oncology. Its pipeline included NeuVax, in Phase 3 development for breast cancer recurrence prevention, and an FBP vaccine in a Phase 1/2 trial. On March 18, 2013, Galena acquired U.S. commercialization rights to FDA-approved Abstral, a fentanyl product for breakthrough cancer pain, and planned a U.S. launch in 2013.
Key financial metrics
| Metric | Q1 2013 | Q1 2012 or comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $5.081 million | $2.664 million |
| General and administrative expense | $1.530 million | $1.746 million |
| Operating loss | $6.611 million | $4.410 million |
| Net loss | $9.293 million; $0.11 per share | $24.761 million; $0.52 per share |
| Net cash used in operating activities | $5.331 million | $4.885 million |
At March 31, 2013, cash and cash equivalents were $17.481 million and marketable securities were $9.709 million, for a combined $27.190 million. Current assets were $27.502 million and current liabilities $26.379 million. Total liabilities were $38.139 million; these included $15.843 million of cash-settleable warrant liabilities and $7.585 million of contingent purchase-price consideration. Capital lease obligations totaled $0.057 million. Stockholders’ equity was $23.312 million.
Q1 investing cash use was $10.087 million, primarily the $10 million Abstral-rights payment. Financing provided $0.092 million. The company reported no revenue, so revenue margins are not applicable.
Material changes versus the prior comparable period
- Net loss narrowed by $15.468 million, approximately 62%, mainly because the fair-value expense on warrant liabilities was lower than in Q1 2012. The warrant fair-value change still generated $5.003 million of Q1 2013 expense.
- R&D expense rose 91%, driven primarily by the Phase 3 PRESENT trial ramp-up.
- Cash and cash equivalents fell $15.326 million from year-end 2012, reflecting the Abstral payment and operating cash use. Marketable securities rose to $9.709 million, representing RXi shares; their unrealized gain contributed $4.269 million to comprehensive income.
- Galena added Abstral rights, with a further $5 million payment due no later than the first anniversary of closing, additional sales milestones, and low-double-digit royalties on future sales.
Outlook, risks and unusual items
- Management expected higher operating costs as it pursued Abstral commercialization and advanced clinical programs. It said existing working capital, including the first $10 million of subsequent loan proceeds, should fund operations through at least Q2 2014; additional funding or product revenue would be needed thereafter.
- After quarter-end, Galena entered into a loan agreement for up to $15 million and drew $10 million on May 8, 2013. The loan bears 8.45% interest, has 12 months of interest-only payments followed by 30 months of amortization, and is secured by company assets other than intellectual property. The additional $5 million tranche was conditional and not assured.
- Management planned an Abstral launch in Q4 2013. Key risks include establishing sales and distribution capabilities, payer coverage, competition from generic and other fentanyl products, third-party manufacturing and supply, DEA controls and quotas for fentanyl, and obligations to Orexo. Failure to meet specified sales-force obligations could allow Orexo to reacquire the U.S. rights for no consideration.
- NeuVax and FBP remain subject to clinical, regulatory, enrollment, and supply risks. The filing cites prior NeuVax trial delays related to GM-CSF supply and continued reliance on a sole source for that component.
- The filing reported no legal proceedings and stated that disclosure controls were effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Galena Biopharma, not SELLAS Life Sciences Group.
- Review the Abstral agreement’s remaining payment, milestone, royalty, sales-force, and reacquisition terms, and confirm the actual launch and sales performance.
- Verify post-quarter loan draws, repayment terms, collateral and covenants, and whether the conditional second tranche became available.
- Assess cash runway against operating burn and expected commercialization and clinical-trial spending; the runway estimate is management’s projection.
- Check the value and liquidity of the RXi shareholding, which made up the marketable securities balance and was subject to equity-price risk.
- Track Phase 3 NeuVax progress and GM-CSF supply, alongside warrant-liability remeasurement and potential share dilution from outstanding warrants and options.